摘要
目的探讨地诺单抗联合唑来膦酸治疗老年骨质疏松症的临床效果。方法抽取周口市中医院2019年1月至2020年9月收治的85例老年骨质疏松患者作为研究对象,依据随机数字表法分为对照组(40例)和观察组(45例)。两组患者均于腹部皮下注射地诺单抗注射液,对照组实施常规治疗(口服钙尔奇D片和活性维生素D),观察组在上述治疗基础上静脉滴注5 mg唑来膦酸注射液,两组患者均连续治疗1年。比较两组的临床疗效,治疗前后骨密度、骨代谢标志物、骨痛、日常生活能力变化情况及不良反应发生率。结果观察组临床总有效率(91.11%,41/45)高于对照组(72.50%,29/40),P<0.05。治疗1年后,两组患者髋部及腰椎骨密度均高于治疗前,且观察组高于对照组(P<0.05)。治疗1年后,两组血清Ⅰ型胶原羧基端肽β特殊序列、抗酒石酸酸性磷酸酶、骨钙素、Ⅰ型胶原氨基末端肽水平均低于治疗前,且观察组低于对照组(P<0.05)。治疗1年后,两组视觉模拟评分法评分均低于治疗前,日常生活活动能力评分高于治疗前,且观察组优于对照组(P<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论唑来膦酸联合地诺单抗治疗老年骨质疏松,可进一步提高临床疗效及骨密度,降低骨代谢指标,改善骨痛及日常生活能力,且安全性高。
Objective To investigate the effect of zoledronic acid combined with denosumab on elderly patients with osteoporosis.Methods A total of 85 elderly patients with osteoporosis treated in Zhoukou Hospital of Traditional Chinese Medicine from January 2019 to September 2020 were selected as the research subjects.They were divided into the control group(40 cases)and the observation group(40 cases)by random number table method.The patients in both groups were injected subcutaneously with denosumab injection in the abdomen.The control group received conventional treatment(oral Calci D tablets and active vitamin D),and the observation group received intravenous infusion of 5 mg zoledronic acid injection based on the above treatment.Both groups were given 1 year of continuous treatment.Clinical effects,changes in bone mineral density,bone metabolism markers,bone pain,activity of daily living,and the incidence of adverse reactions were compared between the two groups.Results The total effective rate of the observation group(91.11%,41/45)was significantly higher than that of the control group(72.50%,29/40),P<0.05.After 1 year of treatment,the bone mineral densities of hip and lumbar vertebra of the two groups were increased,and the observation group had higher bone mineral densities than the control group(P<0.05).After 1 year of treatment,serumβ-isomerized C-terminal telopeptide of type I collagen,tartrate-resistant acid phosphatase 5b,bone gla protein,and N-terminal propeptide of type I procollagen were reduced in the two groups,and they were lower in the observation group than those in the control group(P<0.05).After 1 year of treatment,the visual analogue scale(VAS)score of the two groups were reduced,and the activity of daily living(ADL)scores were increased.Meanwhile,the observation group had better VAS and ADL scores than the control group after 1 year of treatment(P<0.05).There was no significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusions For elderly patients with osteopor
作者
屈唱
夏红涛
Qu Chang;Xia Hongtao(Department of OrthopedicsⅡ,Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou 466000,China)
出处
《中国实用医刊》
2022年第3期116-119,共4页
Chinese Journal of Practical Medicine
关键词
骨质疏松
唑来膦酸
地诺单抗
骨吸收
Osteoporosis
Zoledronic acid
Denosumab
Bone resorption
